These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 26010760)

  • 21. Validation Studies for Microbial Contamination and Control of Contaminants.
    Shintani H
    Biocontrol Sci; 2015; 20(3):161-70. PubMed ID: 26412695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein purification: aspects of processes for pharmaceutical products.
    Berthold W; Walter J
    Biologicals; 1994 Jun; 22(2):135-50. PubMed ID: 7917230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
    Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
    Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A probabilistic model for risk assessment of residual host cell DNA in biological products.
    Yang H; Zhang L; Galinski M
    Vaccine; 2010 Apr; 28(19):3308-11. PubMed ID: 20226252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development.
    den Engelsman J; Garidel P; Smulders R; Koll H; Smith B; Bassarab S; Seidl A; Hainzl O; Jiskoot W
    Pharm Res; 2011 Apr; 28(4):920-33. PubMed ID: 20972611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Target product selection - where can Molecular Pharming make the difference?
    Paul MJ; Teh AY; Twyman RM; Ma JK
    Curr Pharm Des; 2013; 19(31):5478-85. PubMed ID: 23394563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous downstream processing of biopharmaceuticals.
    Jungbauer A
    Trends Biotechnol; 2013 Aug; 31(8):479-92. PubMed ID: 23849674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokine contamination of biological products.
    Wadhwa M; Thorpe R
    Biologicals; 1997 Sep; 25(3):307-18. PubMed ID: 9324999
    [No Abstract]   [Full Text] [Related]  

  • 29. The future of industrial bioprocessing: batch or continuous?
    Croughan MS; Konstantinov KB; Cooney C
    Biotechnol Bioeng; 2015 Apr; 112(4):648-51. PubMed ID: 25694022
    [No Abstract]   [Full Text] [Related]  

  • 30. Advances in plant molecular farming.
    Obembe OO; Popoola JO; Leelavathi S; Reddy SV
    Biotechnol Adv; 2011; 29(2):210-22. PubMed ID: 21115109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New areas of plant-made pharmaceuticals.
    Hassan SW; Waheed MT; Lössl AG
    Expert Rev Vaccines; 2011 Feb; 10(2):151-3. PubMed ID: 21332263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies for Maximizing Successful Drug Substance Technology Transfer Using Engineering, Shake-Down, and Wet Test Runs.
    Abraham S; Bain D; Bowers J; Larivee V; Leira F; Xie J
    PDA J Pharm Sci Technol; 2015; 69(5):650-7. PubMed ID: 26429113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of residual impurities and contaminants on protein stability.
    Wang W; Ignatius AA; Thakkar SV
    J Pharm Sci; 2014 May; 103(5):1315-30. PubMed ID: 24623189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteins improving recombinant antibody production in mammalian cells.
    Nishimiya D
    Appl Microbiol Biotechnol; 2014 Feb; 98(3):1031-42. PubMed ID: 24327213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Large-scale processing of macromolecules.
    Fulton SP
    Curr Opin Biotechnol; 1994 Feb; 5(2):201-5. PubMed ID: 7764801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Automated production of plant-based vaccines and pharmaceuticals.
    Wirz H; Sauer-Budge AF; Briggs J; Sharpe A; Shu S; Sharon A
    J Lab Autom; 2012 Dec; 17(6):449-57. PubMed ID: 23015521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Industrial bioprocessing perspectives on managing therapeutic protein charge variant profiles.
    Chung S; Tian J; Tan Z; Chen J; Lee J; Borys M; Li ZJ
    Biotechnol Bioeng; 2018 Jul; 115(7):1646-1665. PubMed ID: 29532901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Definition of a well-characterized biotechnology product.
    Zoon K; Garnick R
    Dev Biol Stand; 1998; 96():191-7. PubMed ID: 9890531
    [No Abstract]   [Full Text] [Related]  

  • 39. Cellular targets for improved manufacturing of virus-based biopharmaceuticals in animal cells.
    Rodrigues AF; Carrondo MJ; Alves PM; Coroadinha AS
    Trends Biotechnol; 2014 Dec; 32(12):602-7. PubMed ID: 25450042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re-processing strategies for biologicals API manufacturing processes.
    Opitz U
    Dev Biol (Basel); 2003; 113():101-4; discussion 115-6. PubMed ID: 14620858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.